EW-001, our armoured CAR-T product for mesothelioma and other solid cancers is on the threshold of its first US FDA advice and first Australian manufacturing runs, headlining the September 2026 Quarter. Quarter highlights ·       US FDA pre-IND meeting granted for EW-001, scheduled for 4 November 2026 (AEST) representing the program’s first formal US regulatory advice. ·       First Australian manufacturing runs of EW-001 on track for the second half of 2026. ·       EW-001 evidence keeps building: first complete responder passed two years without cancer recurrence, and EW-001 was approved for special access in China’s Hainan province. ·       Manufacturing automation strategy validated by Oribiotech’s 10-year, up to US$120 million commercial agreement for the IRO® platform AdAlta has chosen for future products. ·       Shanghai representative office opened, giving AdAlta the ability to engage local staff and contractors to represent and promote the Company in China. ·       Non-dilutive funding: A$0.23 million R&D Tax Incentive refund received, with further inflows of more than A$1 million expected in the December quarter.